@article{2e692dc1517b41dea91e7fe89a5656d5,
title = "Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis",
abstract = "Background Elevated serum levels of growth differentiation factor-15 (GDF-15), is an established risk factor for a range of cardiovascular diseases. We aimed to evaluate the predictive value of plasma GDF-15 as a biomarker for secondary cardiovascular events (CVE) in patients with atherosclerosis undergoing carotid endarterectomy (CEA). Secondly, we determined whether plasma GDF-15 was associated with carotid plaque characteristics. Methods Circulating GDF-15 levels were determined by Luminex assay in a cohort of 1056 patients from the Athero-Express biobank. Composite endpoint was defined as major CVE, death and peripheral vascular interventions. Findings were validated in 473 patients from the independent Carotid Plaque Imaging Project biobank. Results GDF-15 levels did not associate with secondary CVE in the total cohort. However, following a significant interaction with sex, it was found to be strongly, independently predictive of secondary CVE in women but not men (quartile 4 vs. quartile 1: HR 3.04 [95\% CI 1.35–6.86], p = 0.007 in women vs. HR 0.96 [95\% CI 0.66–1.40], p = 0.845 in men). This was also observed in the validation cohort (women: HR 2.28 [95\% CI 1.04–5.05], p = 0.041), albeit dependent upon renal function. In addition, GDF-15 was associated with the presence of plaque smooth muscle cells and calcification. Conclusion High circulating GDF-15 levels are predictive of secondary CVE in women but not in men with carotid atherosclerotic disease undergoing CEA, suggesting a potential use for GDF-15 as a biomarker for secondary prevention in women. Sex differences in the role of GDF-15 in atherosclerotic disease deserve further interest.",
keywords = "Atherosclerosis, Biomarker, GDF-15, Prognosis, Secondary outcome, Women",
author = "Aisha Gohar and Isabel Gon{\c c}alves and Joyce Vrijenhoek and Saskia Haitjema and \{van Koeverden\}, Ian and Jan Nilsson and \{de Borst\}, \{Gert J.\} and \{de Vries\}, \{Jean Paul\} and Gerard Pasterkamp and \{den Ruijter\}, \{Hester M.\} and Harry Bj{\"o}rkbacka and \{de Jager\}, \{Saskia C.A.\}",
note = "Funding Information: This study was funded by Dutch Heart Foundation (2013T084, Queen of Hearts program). AG was supported by EUTRAIN (European Translational tRaining for Autoimmunity \& Immune manipulation Network), under funding from the 7th Framework program of the EU (FP7-PEOPLE-2011-ITN with the Marie Sklodowska-Curie grant agreement No. 289903). This study was also funded by the Swedish Research Council (K2013-65X-22345-01-3; 2015-02523), the Swedish Heart and Lung Foundation (20140078; 20140327; 20140427) and the Albert P?hlsson Foundation (FB2015-0116). HB is supported by the Swedish Heart and Lung Foundation (20130572). Funding Information: This study was funded by Dutch Heart Foundation (2013T084, Queen of Hearts program). AG was supported by EUTRAIN (European Translational tRaining for Autoimmunity \& Immune manipulation Network), under funding from the 7th Framework program of the EU (FP7-PEOPLE-2011-ITN with the Marie Sklodowska-Curie grant agreement No. 289903). This study was also funded by the Swedish Research Council (K2013-65X-22345-01-3; 2015-02523), the Swedish Heart and Lung Foundation (20140078; 20140327; 20140427) and the Albert P{\aa}hlsson Foundation (FB2015-0116). HB is supported by the Swedish Heart and Lung Foundation (20130572). Publisher Copyright: {\textcopyright} 2017 The Authors",
year = "2017",
month = aug,
day = "15",
doi = "10.1016/j.ijcard.2017.03.101",
language = "English",
volume = "241",
pages = "430--436",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
}